Andere talen Halozyme Therapeutics, Inc.

Aandelen

HALO

US40637H1095

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
38,64 ^USD	+2,20%		+0,08%	+4,55%

18/04	Halozyme Therapeutics Insider verkocht aandelen ter waarde van $768.390, volgens een recent SEC-document	MT
13/03	Halozyme Therapeutics Insider verkocht aandelen ter waarde van $839.100, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	18/04
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	13/03
Halozyme to Participate in Upcoming Investor Conferences	27/02
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	21/02
Halozyme Therapeutics: Q4 Earnings Snapshot	20/02
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	20/02
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	20/02
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	20/02
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	20/02
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	20/02
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	20/02
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	20/02
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	20/02
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	20/02
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	08/02
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	01/02
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	30/01
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	29/01
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	29/01
Halozyme Announces argenx Received Approval in Japan for VYVDURA Co-Formulated with ENHANZE for Generalized Myasthenia Gravis	19/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Halozyme Therapeutics, Inc.

Aandelen

HALO

US40637H1095

Andere talen

Filters